EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models

Ashley V Schwartz, Grace Chao, Mikella Robinson, Brittany M Conley, Mowaffaq Adam Ahmed Adam, Grace A Wells, An Hoang, Elene Albekioni, Cecilia Gallo, Joi Weeks, Katelyn Yunker, Giovanni Quichocho und 5 weitere

Journal of Biological Chemistry · 2025-05 · 301 (5) · 108477

DOI: 10.1016/j.jbc.2025.108477 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025-05. Verfasst von Ashley V Schwartz und 16 weiteren Autor:innen. Beteiligte Einrichtung: Computational Science Research Center, San Diego State University, San Diego, California, USA. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Mutation, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in isocitrate dehydrogenase 1 (IDH1) impart a neomorphic reaction that produces D-2-hydroxyglutarate (D2HG), which can inhibit DNA demethylases to drive tumorigenesis. Mutations affect residue R132 and display distinct catalytic profiles for D2HG production. We show that catalytic efficiency of D2HG production is greater in IDH1 R132Q than R132H mutants, and expression of IDH1 R132Q in cellular and xenograft models leads to higher D2HG concentrations in cells, tumors, and sera compared to R132H. Though expression of IDH1 R132Q leads to hypermethylation in DNA damage pathways, DNA hypomethylation is more notable when compared to IDH1 R132H expression. Transcriptome analysis shows increased expression of many pro-tumor pathways upon expression of IDH1 R132Q versus R132H, including transcripts of EGFR and PI3K signaling pathways. Thus, IDH1 mutants appear to modulate D2HG levels via altered catalysis and are associated with distinct epigenetic and transcriptomic consequences, with higher D2HG levels appearing to be associated with more aggressive tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseMutationNeoplasmsHumansGlutaratesAnimalsMiceDNA MethylationCell Line, TumorPhenotype

Stichwörter der Autor:innen

dehydrogenaseenzyme mutationepigeneticsoncogenetranscriptomics

Substanzen

Isocitrate Dehydrogenasealpha-hydroxyglutarateGlutaratesIDH1 protein, human

Autor:innen und Institutionen

  • Computational Science Research Center, San Diego State University, San Diego, California, USA.
  • Department of Biology, San Diego State University, San Diego, California, USA.
  • Department of Chemistry and Biochemistry, San Diego State University, San Diego, California, USA.
  • Computational Science Research Center, San Diego State University, San Diego, California, USA; Department of Mathematics and Statistics, San Diego State University, San Diego, California, USA.
  • Electron Microscope Facility, San Diego State University, San Diego, California, USA.
  • Neurology Clinic and National Center for Tumor Diseases, Heidelberg University Hospital and Heidelberg University, Heidelberg, Germany. Electronic address: sevin.turcan@med.uni-heidelberg.de.

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • NIH HHS
  • National Cancer Institute
  • National Institutes of Health
  • San Diego State University
  • University of California, San Diego
  • American Cancer Society

Zitieren

APA

Schwartz, A. V., Chao, G., Robinson, M., Conley, B. M., Ahmed Adam, M. A., Wells, G. A., Hoang, A., Albekioni, E., Gallo, C., Weeks, J., Yunker, K., Quichocho, G., George, U. Z., Niesman, I., House, C. D., Turcan, Ş., & Sohl, C. D. (2025). Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models. Journal of Biological Chemistry, 301(5), 108477. https://doi.org/10.1016/j.jbc.2025.108477

Vancouver

Schwartz AV, Chao G, Robinson M, Conley BM, Ahmed Adam MA, Wells GA, et al. Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models. Journal of Biological Chemistry. 2025;301(5):108477. doi:10.1016/j.jbc.2025.108477

BibTeX
@article{Schwartz2025,
  author = {Schwartz, Ashley V and Chao, Grace and Robinson, Mikella and Conley, Brittany M and Ahmed Adam, Mowaffaq Adam and Wells, Grace A and Hoang, An and Albekioni, Elene and Gallo, Cecilia and Weeks, Joi and Yunker, Katelyn and Quichocho, Giovanni and George, Uduak Z and Niesman, Ingrid and House, Carrie D and Turcan, Şevin and Sohl, Christal D},
  title = {Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  volume = {301},
  number = {5},
  pages = {108477},
  doi = {10.1016/j.jbc.2025.108477}
}
Kostenlos starten →